Table 2.
Timing of RAS conversion and ctDNA confirmation test.
| Pt. N. | Bevacizumab | RAS Mutation Tissue/Plasma Baseline | Timing of RAS Conversion (Months) | ctDNA Confirmation Test | |
|---|---|---|---|---|---|
| 1 | no | KRAS G12V | 3 | NGS | TP53 c.524G>A p.R175H |
| 5 | yes | KRAS G12V | 9 | methylation | MSC ITGA4 EYA4 |
| 7 | yes | KRAS G12V | 9 | NGS | SMAD4 c.1522G>T p.G508C |
| 9 | yes | KRAS G12V | 3 | NGS | TP53 c.659A>G p.Y220C |
| 22 | yes | KRAS G12V | 3 | NGS | SMAD4 c.1522G>T p.G508C |
| 27 | yes | KRAS G12V | 9 | NGS | TP53: c.659A>G p.Y220C |
| 39 | yes | KRAS G12V | 6 | NGS | PIK3CA c.1625A>T p.E542V |
| 24 | yes | KRAS G12V | 3 | none | |
| 2 | no | NRAS G12C | 3 | methylation | MAP3K MSC ITGA4 EYA4 |
| 8 | yes | KRAS G12C | 6 | NGS | TP53: c.527G>T p.C176F |
| 26 | yes | KRAS G12C | 3 | methylation | MAP3K EYA4 |
| 33 | yes | KRAS G12C | 12 | NGS | PIK3CA: c.3062A>G p. Y1021C |
| 36 | yes | KRAS G12C | 6 | methylation | MAP3K MSC ITGA4 EYA4 GRIA4 |
| 3 | yes | KRAS G12D | 6 | NGS | TP53 c.743G>A p.R248Q |
| 6 | yes | KRAS G12D | 3 | NGS | PTEN c.209+6T>C |
| 16 | yes | KRAS G12D | 3 | NGS | TP53 c.743G>A p.R248Q |
| 21 | yes | KRAS G12D | 6 | NGS | TP53 c.524G>A p.R175H |
| 23 | yes | KRAS G12D | 9 | none | |
| 28 | yes | KRAS G12D | 3 | NGS | PIK3CA: c.3062A>G p. Y1021C |
| 30 | yes | KRAS G12D | 3 | NGS | TP53 c.844C>T p.R282W |
| 37 | yes | KRAS G12D | 9 | NGS | TP53 c.517G>A p.V173M |
| 34 | yes | KRAS G12D | 6 | none | |
| 35 | yes | KRAS G12D | 9 | NGS | FBXW7 c.1513C>T p.R505C; AKT1 c.49G>A p.E17K |
| 32 | yes | KRAS G12D | 6 | none | |
| 38 | yes | KRAS G12D | 9 | NGS | TP53 c.524G>A p.R175H |
| 43 | yes | KRAS G12D | 12 | NGS | PIK3CA c.1625A>T p.E542V |
| 17 | yes | KRAS G12A | 6 | methylation | MAP3K MSC ITGA4 EYA4 GRIA4 |
| 19 | yes | KRAS G12A | 6 | NGS | PIK3CA c.3140A>G p.H1047R |
| 41 | yes | KRAS G12A | 6 | methylation | EYA4 GRIA4 |
| 14 | yes | KRAS G13D | 3 | NGS | MAP2K1 c.171G>T p.K57N |
| 20 | yes | KRAS G13D | 6 | methylation | MAP3K MSC ITGA4 EYA4 GRIA4 |
| 4 | yes | KRAS A146t | 3 | none | |
| 25 | yes | KRAS A146T | 6 | NGS | TP53 c.817C>T p.T273C |
| 29 | yes | KRAS A146T | 9 | methylation | MAP3K ITGA4 EYA4 GRIA4 |
| 42 | yes | KRAS A146T | 12 | NGS | DDR2 c.1376C>T p.S459F |
| 12 | yes | KRAS Q61K | 3 | NGS | TP53: c.659A>G p.Y220C |
| 13 | yes | KRAS Q61K | 6 | NGS | PIK3CA: c.3062A>G p. Y1021C |
| 40 | yes | KRAS Q61H | 12 | NGS | TP53 c.401T>C p.F134S |
| 11 | yes | NRAS G12D | 3 | NGS | FBXW7 c.1513C>T p.R505C |
| 10 | yes | NRAS G12D | 6 | none | |
| 15 | yes | NRAS G12D | 9 | none | |
| 18 | yes | NRAS A146T | 3 | methylation | ITGA4 EYA4 |
| 31 | yes | NRAS Q61R | 3 | NGS | SMAD4 c.989A>C p.E330A |
Pt: patients; ctDNA: circulating tumor DNA; NGS: next generation sequencing.